ads

Seven Bridges this week announced the close of the first $15 million of a planned $30 million Series C round from a new life sciences investor. This investment will support the company in its mission to accelerate scientific discovery and speed the path from raw experimental data to new treatments and diagnostics.
“Multi-omics tools are fast-becoming ubiquitous drivers of scientific innovation. As the industry’s leading enterprise bioinformatics ecosystem provider, Seven Bridges provides its clients the ability to facilitate discovery by helping researchers generate meaningful insights from vast quantities of data,” said William Moss, chief executive officer of Seven Bridges. “This new investment is a recognition of the leading role Seven Bridges plays in the future of biomedical innovation and will help us continue to innovate and scale our organization to serve our customers’ rapidly-evolving needs to utilize multi-omics data in their research.”
To read more, click here.

Blue Therapeutics, based in Waltham, Massachusetts, has announced a Series A round of funding and has unveiled a disruptive IND stage receptor-interactomicsTM platform and pipeline.
“The fundamental science comes down to the fact that the interaction between receptors creates new drug targets in their own right. They play a much more important role in the biology of many diseases than the single, individual receptors the industry has been historically focusing on.”, explained Ajay Yekkirala, CSO and inventor of the company’s technology. “With the right compounds — we call them interaction modulators — receptor interactions can be selectively manipulated while preserving the physiological function of the individual receptors. This results in distinct and unique pharmacology with improved efficacy and better tissue and disease selectivity and thus eliminating many side-effects we see with current treatments.”.
Blue Therapeutics has been successfully working in an essentially virtual model and has been funded exclusively by public grants of almost $7 million to date. Stefan Bluemmers, CEO and seasoned industry executive, explained the departure.
“We have maxed out the virtual and grant funded model and with the data we have for BLUE-181 and the exciting pipeline we now need to build a company that can effectively drive opportunities forward in parallel. And while we have a very focused pipeline we also know we are really just scratching the surface of a new dimension of drug targets.” To read more, click here.
For more information, contact Stefan Bluemmers at stefan@bluetherapeutics.com

Outcomes4Me, which has an AI platform to help cancer patients to navigate care, raised $12 million in an oversubscribed Series A round. Funding will go towards expanding the company’s platform beyond breast cancer to other cancers and expand to more patients in Europe, among other applications.
Northpond Ventures led the round with participation from existing investors which include Sierra Ventures, Asset Management Ventures, Merstal Ltd, IRA Capital, and others. Andrea Jackson, a Northpond Ventures director, will join Outcomes4Me’s board. To read more, click here.

Health benefits startup Take Command Health has raised $12 million as part of a Series A round. LiveOak Venture Partners and SJF Ventures led the funding round for the Dallas-based business. The company works with small and large employers and offers services for providing coverage to employees typically harder to ensure on a group plan, such as hourly, part-time, or remote workers. To read more, click here.
Picture: akindo, Getty Images

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *